AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Safety, Tolerability, and Lipoprotein(a)-Lowering Effect of HRS-5632, an Extended Long-Acting Small Interfering RNA Targeting Lipoprotein(a): A Randomized, Double-Blind, First-in-Human Study

By Li N, Kong W, Zhu Y et al.

Background: Given the causal role of lipoprotein(a) in ASCVD pathogenesis, pharmacologically reducing lipoprotein(a) levels has emerged as a promising strategy for mitigating residual cardiovascular risk. HRS-5632 is a small interfering RNA designed to silence LPA expression, leading to the degradation of apolipoprotein(a) mRNA and thereby preventing lipoprotein(a) particle assembly in hepatocytes. This first-in-human study aimed to assess the safety, tolerability, pharmacodynamics, and immunogenicity of HRS-5632 in healthy participants. Methods: In this randomized, double-blind, single ascending dose, phase 1 study, adults aged 18 to 55 years with a lipoprotein(a) concentration of ≥75 nmol/L (30 mg/dL) were eligible. Doses escalated from 2 to 400 mg. Participants in each dose cohort were randomly assigned (4:1) to receive a single subcutaneous dose of HRS-5632 or matching placebo. Results: Of the 50 enrolled participants, 40 received HRS-5632 (n=8 per dose cohort) and 10 received placebo. The median lipoprotein(a) level at baseline was 138.8 nmol/L (IQR, 83.7-192.7). Following HRS-5632 treatment, a sharp decline in lipoprotein(a) was observed, with the maximum reduction achieved on day 29 (Figure). HRS-5632 at 10 mg or higher could reduce lipoprotein(a) by ≥90%. Notably, the ≥90% reduction after a single dose of 200 mg or 400 mg of HRS-5632 persisted for approximately one year. At week 48, 87.5% of participants in the 200 mg cohort and 100.0% in the 400 mg cohort still achieved ≥90% lipoprotein(a) reduction. Moreover, all participants in the two dose cohorts had lipoprotein(a) levels reduced to ≤50 nmol/L. Treatment-related adverse events (TRAEs) were generally comparable between the HRS-5632 and placebo groups (52.5% vs. 40.0%). All TRAEs were mild in severity. No serious TRAEs occurred, and there were no injection site reactions. No clinically significant changes in plasminogen activity were observed. No treatment- or dose-related liver enzyme elevations were noted. Anti-drug antibodies were not detected. Conclusions: HRS-5632 at up to 400 mg was well-tolerated and produced durable and substantial reductions in lipoprotein(a), supporting its further development for once-yearly administration.

doi.org/10.1161/circ.154.suppl_1.6307Interventions

AgingResearch.News